NYSEAMERICAN:TOVX Theriva Biologics Q4 2025 Earnings Results & Report $0.15 -0.01 (-8.13%) As of 12:40 PM Eastern This is a fair market value price provided by Massive. Learn more. Theriva Biologics reported Q4 2025 earnings on March 12, 2026. The company reported EPS of $1.30. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Theriva Biologics EPS ResultsActual EPS$1.30Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATheriva Biologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Theriva Biologics Q4 2025 Earnings FAQ Did Theriva Biologics beat earnings estimates for Q4 2025? Theriva Biologics (NYSEAMERICAN:TOVX) reported earnings of $1.30 per share for Q4 2025. The report was announced on Thursday, March 12, 2026. Theriva Biologics Earnings HeadlinesTheriva Biologics, Inc.: Theriva Biologics Reports Third Quarter 2026 Operational Highlights and Financial ResultsNovember 12 at 11:16 AM | finanznachrichten.deTheriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial ResultsNovember 12 at 8:00 AM | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 13 at 1:00 AM | Weiss Ratings (Ad)Theriva Biologics Sells Enzyme Portfolio; Shifts Focus To VCN-01; Stock UpNovember 3, 2026 | rttnews.comTheriva Biologics consensus price target raised 60% to $4.08November 3, 2026 | msn.comTheriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.November 2, 2026 | globenewswire.comSee More Theriva Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theriva Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theriva Biologics and other key companies, straight to your email. Email Address About Theriva BiologicsTheriva Biologics (NYSEAMERICAN:TOVX) is a clinical-stage biotechnology company developing treatments based on microbiome science and cancer immunotherapy. The company focuses on therapeutics intended to address serious diseases with limited treatment options, including cancer and conditions associated with disruption of the intestinal microbiome. Its lead candidate, VCN-01, is a genetically engineered oncolytic adenovirus designed to selectively replicate in and destroy tumor cells while stimulating an immune response against cancer. Theriva has evaluated VCN-01 in clinical studies involving pancreatic cancer and other solid tumors, including combinations with existing cancer treatments. Theriva has also developed microbiome-focused candidates, including ribaxamase, an orally administered enzyme designed to break down certain intravenous beta-lactam antibiotics in the gastrointestinal tract. The program is intended to help preserve beneficial gut bacteria and potentially reduce complications associated with antibiotic-related microbiome disruption. The company operates internationally through its U.S. corporate organization and research and development activities in Europe.View Theriva Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
